Latest Conference Articles

New ADA 2026 data show diabetic ketoacidosis hospitalizations rising 24%, driven by poor ketone monitoring and symptom recognition gaps across all ages.

PROTEUS results reshape high‑risk localized prostate cancer care, adding apalutamide plus androgen deprivation before surgery as a new option.

The dual glucagon/GLP-1 receptor agonist is also being studied in the SYNCHRONIZE-2, SYNCHRONIZE-CVOT, LIVERAGE, and LIVERAGE-Cirrhosis trials.

By controlling for ovarian suppression, OPTIMA shows Prosigna works equally well in pre and postmenopausal high-risk early breast cancer.

Research from Samuel Shangwu Wu, PhD, presented as an ADA Presidents' Select Abstract, proposes a better way to measure beta-cell preservation.

Remote therapeutic monitoring (RTM) with ePROs powered by AI cuts hospitalizations and boosts therapy time—now a key oncology leader promotes guideliens and reimbursement to make it standard of care.

Four experts examine what updated dietary and obesity guidelines mean for diabetes care, and why personalized, equitable nutrition is now essential.

Anne Komé, PharmD, explains that diabetes drug development is shifting to concurrent testing of metabolic effects.

ADA 2026 research showed how oral ketones, irisin, and SGLT2 inhibitors may reveal new metabolic pathways beyond glucose control.

ADA 2026 data show survodutide cut visceral fat by 34% and liver fat by 63%, suggesting metabolic benefits beyond weight loss in phase 3 trials.

Diet quality, carbohydrate quantity, and macronutrient composition may influence gestational glycemia, with consequences well into the postpartum period.

The next frontier, according to Igor Puzanov, MD, MSCI, FACP, includes improving immune toxicity recognition and long-term care.

Two new studies reveal how social determinants shape cognitive risk in prediabetes and type 2 diabetes, complicating the path to prevention.

Diabetes disparities drive unequal CGM access and amputation risk, highlighting the need to address social, provider, and policy barriers to equitable care.

At ADA 2026, Alyson K. Myers, MD, explains why knowing your community—and meeting patients where they are—is key to better diabetes outcomes and lower costs.

AI tools for carbohydrate estimation and clinical decision support are reshaping how diabetes is managed, but human oversight remains essential.

ADA 2026: Inhaled insulin (Afrezza) shows comparable HbA1c and time-in-range to rapid-acting analogs in youth, with greater treatment satisfaction reported.

After FDA approval for children 6 and older, ADA data show inhaled insulin's safety and satisfaction benefits, but clinician awareness remains a key barrier.

The 2026 EHA Congress, convening in Stockholm next week, will bring the global hematology community together for 4 days of science, debate, and discovery.

OPTIMA trial data show genomic testing helps many patients with high‑risk breast cancer skip chemotherapy safely and start endocrine therapy sooner.

Late-breaker data from EASL Congress 2026 mark a pivotal moment in chronic hepatitis B research.

Canopy remote therapeutic monitoring with ePROs cuts hospitalizations and extends time to discontinuation in metastatic cancer, saving millions.

MASH cirrhosis treatment, fibrosis reversal, and population screening were cited by experts as hepatology's biggest gaps.

Chemotherapy decisions for young women with HR+ breast cancer and low recurrence scores reveal testing disparities that health systems must address.

An AI-driven review of oncology trials reveals that diversity progress over 30 years is largely an illusion driven by Asian enrollment growth.

Alexa Simon Meara, MD, MS, discusses breaking down silos between academic and community oncology to improve immunotherapy care and irAE management.

Longer-term data support pimicotinib as an effective, well-tolerated option for a rare benign tumor that can cause significant joint disability.

From cardiovascular risk to missed toxicity grading, Igor Puzanov, MD, MSCI, outlines what is failing in checkpoint inhibitor toxicity management.